Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion
Amoytop Biotech Co. Ltd. (SHA: 688278) released its prospectus for convertible bond issuance to unspecified...
Amoytop Biotech
Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir
Amoytop Biotech Co., Ltd. (SHA: 688278), a leading Chinese biopharmaceutical company, has entered into a...
Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B
Amoytop Biotech Co. Ltd. (SHA: 688278) announced today that the National Medical Products Administration (NMPA)...
Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...
Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC
Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech...
Tonghua Dongbao to Sell Stake in Amoytop Biotech for USD 181 Million
Chinese pharmaceutical firm Tonghua Dongbao Pharmaceuticals Co., Ltd (SHA: 600867) has announced plans to divest...
Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...
Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced that it has received clinical trial...
NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China
NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...
Amoytop Biotech Opts for NASH Drug Candidate KN069 in Licensing Deal with Alphamab Oncology
Xiamen Amoytop Biotech Co., Ltd (SHA: 688278), a biopharmaceutical company based in China, has exercised...
Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy
Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...
Amoytop Biotech’s Peginterferon α-2b Receives NMPA Approval for Primary Thrombocytosis Clinical Trial
Amoytop Biotech Co. Ltd (SHA: 688278), based in Xiamen, has announced that it has received...
Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...
Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...
Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D
Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership...
Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment
Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...